Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: $22M in Earnings Needed for $1 pps?

Yes, thanks for reposting that. I remember reading it when you shared it previously. While I sure would love to see guidance and think it would be a welcome sight from the markets perspective, it doesn't appear we'll get it anytime soon.



However, what I was asking for in my post that you responded to isn't guidance per se, but more a framework by RG as to what the potential of the market that PTSC sees specifically for itself, with the Crossflo acquisition and the SSDI & Talis peices in place. I'm not asking that he predict that they'll reach a certain level, but to somehow give us some insight that says something to the effect that the potential market that PTSC is going after could be $100M or $200M per year, and that they have a target once fully integrated of delivering the operational peice of the company business at say 35% margins or something similar. Just something that can help the market understand the potential and to give some insight into the profit margins available.

Share
New Message
Please login to post a reply